Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1

Published:2022-01-22 Issue:1 Volume:11 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Quixabeira Dafne C. A.¹^ORCID,Cervera-Carrascon Victor¹²^ORCID,Santos Joao M.¹²,Clubb James H.A.¹²,Kudling Tatiana V.¹^ORCID,Basnet Saru¹,Heiniö Camilla¹^ORCID,Grönberg-Vähä-Koskela Susanna¹³,Anttila Marjukka⁴^ORCID,Havunen Riikka¹²,Kanerva Anna⁵,Hemminki Akseli¹²³^ORCID

Affiliation:

1. Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

2. TILT Biotherapeutics, Helsinki, Finland

3. Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

4. Pathology, Finnish Food Authority, Helsinki, Finland

5. Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland

Funder

Suomen Kulttuurirahasto

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2022.2028960

Reference52 articles.

1. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

2. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

3. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

4. Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond

5. Cancer immunotherapy: Pros, cons and beyond

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trial watch: local anesthetics in cancer therapy;OncoImmunology;2024-03-17

2. Novel technologies for applying immune checkpoint blockers;International Review of Cell and Molecular Biology;2024

3. Balancing safety and efficacy: tuning the biodistribution and pharmacokinetics of cytokine immunotherapies;Current Opinion in Biotechnology;2023-12

4. Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model;Frontiers in Oncology;2023-11-20

5. Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer;Cancer Gene Therapy;2023-11-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3